Skip to main content

Hepatocellular Carcinoma Topic Center

Featured

Dan Brown
Daniel Brown, MD, FSIR reviews noteworthy 2022 studies on liver metastatic disease at the Symposium on Clinical Interventional Oncology.
01/04/2023
Riad Salem, MD, MBA
Riad Salem, MD, MBA presents notable studies from 2022 at the Symposium on Clinical Interventional Oncology.
01/01/2023
Brennan Cronquist
CIO2022 Highlights
10/27/2022
B. Cronquist, 4th year medical student at the George Washington University School of Medicine and Health Sciences, discusses his CIO2022 abstract, "CIO 2022-6 Irreversible Electroporation versus Radiofrequency Ablation as a Treatment Option...
B. Cronquist, 4th year medical student at the George Washington University School of Medicine and Health Sciences, discusses his CIO2022 abstract, "CIO 2022-6 Irreversible Electroporation versus Radiofrequency Ablation as a Treatment Option...
B. Cronquist, 4th year medical...
10/27/2022
IO Learning
Dr Edward Kim
CIO2022 Highlights
10/26/2022
Dr Edward Kim discusses his CIO2022 abstract, "Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma."
Dr Edward Kim discusses his CIO2022 abstract, "Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma."
Dr Edward Kim discusses his...
10/26/2022
IO Learning
News
10/24/2022
American Society for Radiation Oncolo...
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial indicates SBRT is an option for patients ineligible for other local therapies
Randomized phase III trial...
10/24/2022
IO Learning
Purpose: Locoregional therapies such as transarterial chemoembolization (TACE) are the most common treatments for patients with intermediate-stage hepatocellular carcinoma (HCC). Although...
10/18/2022
Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000, which has steadily increased from 1992, when there was an incidence of 4.1 per 100,000. ...
10/18/2022
Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000 and is the most common cause of primary liver cancer worldwide. The gold-standard treatme...
10/18/2022
Purpose: To evaluate predictors of overall survival in patients with hepatocellular carcinoma (HCC) treated with lipiodol transarterial chemoembolization (cTACE).
10/18/2022
Purpose: To analyze the response and survival benefits of transarterial radioembolization (TARE) with iodine-131 Lipiodol for hepatic metastases.
10/18/2022